​

Palvella Therapeutics (PVLA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PVLA Stock Forecast

Palvella Therapeutics (PVLA) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $126.63, with a high of $200.00 and a low of $80.00. This represents a 37.78% increase from the last price of $91.91.

PVLA Stock Rating

Palvella Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 1 Strong Buy (12.50%), 7 Buy (87.50%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 7 1 Strong Sell Sell Hold Buy Strong Buy

PVLA Price Target Upside V Benchmarks

TypeNameUpside
StockPalvella Therapeutics37.78%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts41015
Avg Price Target$165.75$121.30$97.93
Last Closing Price$91.91$91.91$91.91
Upside/Downside80.34%31.98%6.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-12---12
Nov, 25310---13
Oct, 25310---13
Sep, 2539---12
Aug, 2528---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 04, 2025Albert LoweCraig-Hallum$175.00$91.9190.40%90.40%
Nov 24, 2025Samimy AnnabelStifel Nicolaus$145.00$94.0954.11%57.76%
Nov 19, 2025Raymond James$143.00$96.9147.56%55.59%
Nov 06, 2025Cantor Fitzgerald$200.00$81.08146.67%117.60%
Oct 09, 2025Canaccord Genuity$90.00$74.8520.24%-2.08%
Oct 07, 2025Cantor Fitzgerald$120.00$71.3868.11%30.56%
Oct 02, 2025Danielle BrillTruist Financial$80.00$61.6929.68%-12.96%
Sep 25, 2025H.C. Wainwright$95.00$57.6964.67%3.36%
Sep 24, 2025Annabel SamimyStifel Nicolaus$80.00$59.8733.62%-12.96%
Sep 09, 2025Oppenheimer$85.00$56.7149.89%-7.52%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 04, 2025Craig-HallumBuyinitialise
Nov 11, 2025OppenheimerOutperformOutperformhold
Nov 06, 2025Cantor FitzgeraldOverweightOverweighthold
Oct 07, 2025Cantor FitzgeraldOverweightOverweighthold
Sep 25, 2025H.C. WainwrightBuyBuyhold
Sep 09, 2025OppenheimerOutperforminitialise
Aug 15, 2025H.C. WainwrightBuyBuyhold
Aug 05, 2025Raymond JamesOutperforminitialise
Mar 07, 2025ScotiabankOutperforminitialise
Dec 18, 2024Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-7.83---
Avg Forecast$-3.70$-2.77$-5.41$-2.81
High Forecast$-3.02$-1.60$-1.48$-1.37
Low Forecast$-4.37$-3.93$-12.67$-4.16
Surprise %111.62%---

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast$50.00K--$5.62M
High Forecast$50.00K--$5.62M
Low Forecast$50.00K--$5.62M
Surprise %----

Net Income Forecast

$-30M $-24M $-18M $-12M $-6M $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-17.43M---
Avg Forecast$-8.22M$-6.15M$-15.75M$-6.15M
High Forecast$-6.72M$-3.56M$-3.29M$-3.05M
Low Forecast$-9.73M$-8.75M$-28.20M$-9.26M
Surprise %111.97%---

PVLA Forecast FAQ

Is Palvella Therapeutics stock a buy?

Palvella Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Palvella Therapeutics is a favorable investment for most analysts.

What is Palvella Therapeutics's price target?

Palvella Therapeutics's price target, set by 8 Wall Street analysts, averages $126.63 over the next 12 months. The price target range spans from $80 at the low end to $200 at the high end, suggesting a potential 37.78% change from the previous closing price of $91.91.

How does Palvella Therapeutics stock forecast compare to its benchmarks?

Palvella Therapeutics's stock forecast shows a 37.78% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Palvella Therapeutics over the past three months?

  • December 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 23.08% Strong Buy, 76.92% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 23.08% Strong Buy, 76.92% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Palvella Therapeutics’s EPS forecast?

Palvella Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.77, marking a -64.62% decrease from the reported $-7.83 in 2024. Estimates for the following years are $-5.41 in 2026, and $-2.81 in 2027.

What is Palvella Therapeutics’s revenue forecast?

Palvella Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, and $5.62M for 2027.

What is Palvella Therapeutics’s net income forecast?

Palvella Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-6.155M, representing a -64.70% decrease from the reported $-17.434M in 2024. Projections indicate $-15.748M in 2026, and $-6.155M in 2027.